Adaptin Bio (APTN) Total Liabilities (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Total Liabilities data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 123.83% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 123.83% YoY), and the FY2025 full-year result was $2.1 million, down 51.41% from the prior year.
• Total Liabilities improved to $2.5 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $4.3 million in Q4 2024 to a low of $27804.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $672190.0 in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 3730.9% in 2024 and sank 51.41% in 2025, its largest moves.
• Tracing APTN's Total Liabilities over 5 years: stood at $27804.0 in 2022, then soared by 307.41% to $113277.0 in 2023, then jumped by 3730.9% to $4.3 million in 2024, then slumped by 51.41% to $2.1 million in 2025, then gained by 17.7% to $2.5 million in 2026.
• Business Quant data shows APTN's Total Liabilities at $2.5 million in Q1 2026, $2.1 million in Q4 2025, and $1.9 million in Q3 2025.